Enhanced-affinity anti-ecm nanobody-cytokine fusions and their applications
AssigneeMassachusetts Institute of Technology
InventorsRichard O. Hynes, Karl Dane Wittrup, Noor Jailkhani, Noor Momin, Emi Lutz
Life of this patent
Estimating the term…
Abstract
Provided herein are anti-FN-EIIIB nanobodies, conjugates thereof, and methods of using the nanobodies and conjugates thereof.
Claims30
A nanobody that binds specifically to the EIIIB domain of fibronectin and comprises:
- a) a complementarity-determining region (CDR) 1 comprising G(S/R/I/N)TFSH(N/S/Y/K)AG(G/S);
- b) a CDR2 comprising (G/R)(I/V)(S/R/G/N)S(D/A/Y)GNI(N/S);
- and
- c) a CDR3 comprising NIRG(S/T)YG(N/S)TYY(S/R)R,
- wherein the nanobody does not comprise SEQ ID NO:
- 1.
(canceled)
-8. (canceled)
(canceled)
-13. (canceled)
-18. (canceled)
-28. (canceled)
(canceled)
(canceled)
A nanobody cytokine fusion protein, comprising a nanobody that binds specifically to the EIIIB domain of fibronectin fused to a cytokine, optionally wherein the cytokine is selected from IL-2, IL-6, IL-8, IL-10, IL-12, IL-18, TNF, IFN-γ, IFN-β, chemokines, and IFN-α and their mutants.
(canceled)
-44. (canceled)
Dependencies are inferred from the claim text.